- Home
- GYRE vs BCX Comparison
GYRE vs BCX Comparison
Compare GYRE & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- BCX
- Stock Information
- Founded
- GYRE 2002
- BCX 2011
- Country
- GYRE United States
- BCX United States
- Employees
- GYRE N/A
- BCX N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- GYRE Health Care
- BCX Finance
- Exchange
- GYRE Nasdaq
- BCX Nasdaq
- Market Cap
- GYRE 755.7M
- BCX 750.9M
- IPO Year
- GYRE N/A
- BCX N/A
- Fundamental
- Price
- GYRE $8.19
- BCX $10.30
- Analyst Decision
- GYRE Strong Buy
- BCX
- Analyst Count
- GYRE 2
- BCX 0
- Target Price
- GYRE $17.00
- BCX N/A
- AVG Volume (30 Days)
- GYRE 60.0K
- BCX 370.6K
- Earning Date
- GYRE 11-07-2025
- BCX 01-01-0001
- Dividend Yield
- GYRE N/A
- BCX 6.99%
- EPS Growth
- GYRE N/A
- BCX N/A
- EPS
- GYRE 0.04
- BCX N/A
- Revenue
- GYRE $107,265,000.00
- BCX N/A
- Revenue This Year
- GYRE $15.25
- BCX N/A
- Revenue Next Year
- GYRE $33.14
- BCX N/A
- P/E Ratio
- GYRE $211.54
- BCX N/A
- Revenue Growth
- GYRE 2.13
- BCX N/A
- 52 Week Low
- GYRE $6.11
- BCX $8.25
- 52 Week High
- GYRE $19.00
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- BCX 67.45
- Support Level
- GYRE $7.12
- BCX $9.70
- Resistance Level
- GYRE $7.42
- BCX $9.92
- Average True Range (ATR)
- GYRE 0.34
- BCX 0.11
- MACD
- GYRE 0.04
- BCX 0.06
- Stochastic Oscillator
- GYRE 94.82
- BCX 93.31
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.